Days
Hours
Minutes
Seconds
-40%
on all subscriptions*
Last hours
Enjoy this offer
* See conditions under "Our services"

Valuation: Fortress Biotech, Inc.

Market Cap 99.33M 86.6M 80.21M 75.08M 141M 9.37B 142M 952M 369M 4.61B 373M 365M 16.02B P/E 2026 *
1.25x
P/E 2027 * 5.92x
Enterprise Value 99.33M 86.6M 80.21M 75.08M 141M 9.37B 142M 952M 369M 4.61B 373M 365M 16.02B EV / Sales 2026 *
1.24x
EV / Sales 2027 * 0.74x
Free-Float
77.21%
Yield 2026 *
-
Yield 2027 * -
1 day-2.61%
1 week+7.94%
Current month+6.79%
1 month+18.18%
3 months-4.78%
6 months-15.54%
Current year-18.31%
1 week 2.8
Extreme 2.8
3.16
1 month 2.53
Extreme 2.526
3.16
Current year 2.18
Extreme 2.18
4.53
1 year 1.7
Extreme 1.7
4.53
3 years 1.24
Extreme 1.24
10.35
5 years 1.24
Extreme 1.24
57.15
10 years 1.24
Extreme 1.24
91.5
Manager TitleAgeSince
Chief Executive Officer 71 20/12/2013
Director of Finance/CFO 51 22/02/2012
Director of Finance/CFO 36 16/08/2022
Director TitleAgeSince
Director/Board Member 74 01/12/2008
Chairman 71 20/12/2013
Director/Board Member 63 01/06/2006
Date Insider Type Main position Quantity % Market Cap.
04-01Free

Chief Financial Officer

2,967 0.0096%
03-18Free

Chief Executive Officer

475,424 1.5318%
03-18Free

Director

475,424 1.5318%
Change 5-day change 1-year change 3-year change Capi.($)
-2.61%+7.94%+65.19%-71.92% 99.33M
+0.33%-0.36%+18.76%-22.11% 62.05B
+0.20%-9.17%+58.39%+196.56% 54.45B
-3.92%+37.40%+37.40%+37.40% 43.09B
+7.62%+8.19%-51.27%-59.11% 36.37B
-1.05%-1.73%+55.35%-33.92% 29.02B
+3.50%+28.15%+151.81%-50.31% 25.38B
-0.78%-9.50%+43.87%+55.34% 19.62B
+1.74%-0.39%-2.93%+113.90% 16.89B
-0.05%+0.23%+61.48%+101.93% 15.93B
Average +0.50%+2.59%+43.81%+26.78% 30.29B
Weighted average by Cap. +0.70%+0.79%+37.46%+36.83%

Financials

2026 *2027 *
Net sales 79.88M 69.64M 64.5M 60.38M 113M 7.54B 114M 765M 297M 3.71B 300M 293M 12.88B 134M 117M 108M 101M 190M 12.66B 191M 1.29B 498M 6.23B 504M 493M 21.63B
Net income 90.51M 78.92M 73.09M 68.42M 128M 8.54B 129M 867M 336M 4.2B 340M 332M 14.6B 21.13M 18.42M 17.06M 15.97M 29.96M 1.99B 30.14M 202M 78.45M 981M 79.32M 77.62M 3.41B
Net Debt - -
Logo Fortress Biotech, Inc.
Fortress Biotech, Inc. is a biopharmaceutical company focused on acquiring and advancing assets. The Company has eight marketed prescription pharmaceutical products and over 20 programs in development, with its majority-owned and majority-controlled partners and subsidiaries and partners and subsidiaries it founded and in which it holds significant minority ownership positions. Its portfolio is being commercialized and developed for various therapeutic areas, including oncology, dermatology, and rare diseases. Its dermatology products include Emrosi, Qbrexza, Amzeeq, Zilxi, Exelderm, Targadox, and Luxamend. Its late-stage product candidates include CUTX-101 (copper histidinate injection for Menkes disease), Triplex (cytomegalovirus (CMV) vaccine), and CAEL-101 (monoclonal antibody for AL amyloidosis). Its early and mid-stage product candidates include Dotinurad (urate transporter (URAT1) inhibitor for gout), MB-101 (IL13Rα2 CAR T Cell Program for Glioblastoma), and others.
Employees
78
Date Price Change Volume
18/06/26 2.990 $ -2.61% 372,256
17/06/26 3.070 $ +4.78% 689,378
16/06/26 2.930 $ +2.45% 375,026
15/06/26 2.860 $ +3.25% 463,991
12/06/26 2.770 $ +0.36% 286,074
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
2.990USD
Average target price
11.00USD
Spread / Average Target
+267.89%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. FBIO Stock
LAST HOURS | 40% Discount: The Best Subscriber-Only Tools to Unlock Hidden Opportunities!
d
:
:
SEIZE THE OFFER!